|Dr. Christopher J. Martin||Co-Founder, CEO & Director||N/A||N/A||1959|
|Mr. Michael Forer L.L.B.||Vice Chairman, Exec. VP & Gen. Counsel||N/A||N/A||1966|
|Ms. Jennifer Creel||Chief Financial Officer||N/A||N/A||1971|
|Mr. Robert A. Schmidt||VP, Corp. Controller & Chief Accounting Officer||N/A||N/A||1977|
|Amanda Hamilton||Investor Relations Officer||N/A||N/A||N/A|
|Ms. Susan Romanus||Chief Compliance Officer||N/A||N/A||1966|
|Dr. Peter Greaney Ph.D.||Head of Corp. Devel.||N/A||N/A||1980|
|Ms. Kimberly Pope||Sr. VP & Chief HR Officer||N/A||N/A||1967|
|Dr. Patrick van Berkel||Sr. VP of R&D||N/A||N/A||1969|
|Dr. Jay M. Feingold M.D., Ph.D.||Chief Medical Officer, Head of Oncology Clinical Devel. & Sr. VP||N/A||N/A||1957|
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADC Therapeutics SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.